Number of participants experiencing one or more episodes requiring hospital admission · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Total number of withdrawals · episodic viral wheeze in children
Maintenance LTRA showed no clear difference in withdrawals ‐ Total number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing one or more episode requiring treatment with oral steroids · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episode requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episodes requiring ED visit · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing one or more episodes requiring hospital admission · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in number of participants experiencing one or more episodes requiring… compared with placebo (moderate certainty).
1 finding from 1 review
Total number of withdrawals · episodic viral wheeze in children
Intermittent LTRA showed no clear difference in withdrawals ‐ Total number of withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of exacerbations of bronchiectasis Frequency of acute exacerbations of bronchiectasis · individuals with stable bronchiectasis
The intervention showed no clear difference in number of exacerbations of bronchiectasis Frequency of acute… (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations · individuals with stable bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life (disease‐specific) Scale from 0 to 100; lower score indicates better HRQoL. SGRQ total score consists of weighted scores from 3 domains · individuals with stable bronchiectasis
1 finding from 1 review
Intervention not reported
Health‐related quality of life (cough‐specific) Leicester Cough Questionnaire Scale from 0 to 133; higher score indicates better HRQoL. Contains 19 questions from 3 domains on a Likert scale · individuals with stable bronchiectasis
1 finding from 1 review
Intervention not reported
Health‐related quality of life (health status) COPD Assessment Tool. Scale from 0 to 5; higher score indicates worse HRQoL Contains 10 questions with 5‐point Likert scale · individuals with stable bronchiectasis
The intervention showed no clear difference in health‐related quality of life (health status) COPD Assessment Tool.… (low certainty).
1 finding from 1 review
Intervention not reported
Respiratory symptoms (symptoms) Breathlessness, Cough and Sputum Scale Scale from 0 to 12. Lower score indicates fewer symptoms · individuals with stable bronchiectasis
The intervention showed no clear difference in respiratory symptoms (symptoms) Breathlessness, Cough and Sputum… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (AEs) · individuals with stable bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with tiotropium alone (moderate certainty).
1 finding from 1 review